Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Clinical trial NCT05145361 · RECRUITING

Trial details

NCT number: NCT05145361
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

NMO Spectrum Disorder

Start date: 2022-04-07
Primary completion: 2026-12-15
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.